Share on StockTwits

Shares of Cara Therapeutics (NASDAQ:CARA) saw a large decrease in short interest in August. As of August 15th, there was short interest totalling 498,943 shares, a decrease of 34.0% from the July 31st total of 755,917 shares, American Banking and Market News reports. Based on an average trading volume of 111,433 shares, the short-interest ratio is presently 4.5 days. Approximately 5.1% of the shares of the stock are short sold.

Cara Therapeutics (NASDAQ:CARA) opened at 10.28 on Thursday. Cara Therapeutics has a 52-week low of $9.648 and a 52-week high of $23.25. The stock has a 50-day moving average of $11.48 and a 200-day moving average of $14.7. The company’s market cap is $232.8 million.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.27) by $0.11. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.08 million. Cara Therapeutics’s revenue was down 90.4% compared to the same quarter last year. Analysts expect that Cara Therapeutics will post $-0.84 EPS for the current fiscal year.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.